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Abstract
Purpose Symptoms of the oral cavity clearly encompass
more than radiation or chemotherapy-induced mucositis.
Still, the burden of oral symptoms in palliative care has
hardly been addressed directly, and considerations towards
underlying disease processes have often been extrapolated
from oncology patients.
Methods We therefore conducted a prospective explorative
survey with pilot character on patients on a specialized
palliative care unit, describing symptom pattern (self
assessment), clinical signs, bacteriological, mycological
and virological findings, and correlating features of clinical
history.
Results Taste disturbances, dry mouth and the presence of
Candida were found to be the most prevalent and
correlating items. The broad spectrum of further symptoms,
signs and findings did not show relevant correlations and
did not permit any unilateral causal attributions.
Conclusions Apart from the described focus on Candida
colonisation/infections, a symptom-guided polypragmatic
approach therefore seems to be justifiable for patients with
oral symptoms in palliative care.
Keywords Palliative care.Oral symptoms.Taste
disturbances.Dry mouth.Candida
Introduction
As compared to “typical” symptoms and clinical problems
in palliative care like pain, dyspnoea and nausea [1],
symptoms of the oral cavity have drawn little attention up
to date. In a large national survey (the German Hospice and
Palliative Care Evaluation), the prevalence of oral symp-
toms like dysphagia or dry mouth have been rated by staff
to be 3.5% or even below [2]. The multifaceted (medical,
nursing or psychosocial) aspects of oral care in palliative
care patients, underlined also in this survey, and day-to-day
clinical practice suggest a broader symptom spectrum and a
higher subjective relevance than epidemiological studies
might imply.
Background information concerning possible causes of
oral symptoms, their underlying clinical or microbiological
features or standardised treatment concepts are described
predominantly for oncological patients, receiving medical
anticancer therapy or radiation therapy. For this group of
patients, aspects of treatment-related oral and mucosal
toxicity (i.e. mucositis, treatment-related xerostomy) have
been described in detail [3, 4], and well-proven treatment
recommendations exist (Multinational Association of Sup-
portive Care in Cancer; [5]).
In advanced cancer and in palliative care, though, oral
complications and the underlying causes for oral symptoms
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local findings and local microbiological features have been
addressed to a much lesser extent until recently [6, 7]
We therefore performed the following pilot study in
order to assess the subjective symptom burden, the
prevalences of clinical and microbiological oral findings
and to generate hypotheses about possible underlying
correlations. Thereby, we intended to contribute on defining
causal relations between subjective symptoms and objective
findings and resulting therapeutic implications specifically
for the group of palliative care patients.
Methods
Study design and patients
We conducted a prospective single center survey, focussing
on all inpatients consecutively admitted on our palliative
care unit. Exclusion criteria comprised inability to take part
due to the underlying clinical status, or unwillingness to
give informed consent.
The survey was conducted in a five-step approach:
after written information and informed consent, a
thorough history was taken, including medications and
prior or concurrent anticancer therapies. Patients were
requested to assess their general symptom burden by
using the four-step Minimal Documentation Scale
(Midos) [8] and the intensity of specific oral symptoms
using numerical rating scales (NRS). A physical exami-
nation of the oral cavity was performed by an approved
dentist. Documentation comprised semiquantitative item
scales, multiple choice and open questions, and the
decayed/missing/filled teeth (DMF-T) score as a rough
measure on prevalence of caries (www.whocollab.od.mah.
se/expl/orhdmft.html) .Am o u t hs w a b( T r a n s y s t e m ® )w a s
taken from buccal mucosa, the palatal ring and tongue and
sent for semiquantitative bacteriological and mycological
c u l t u r e ,f o l l o w e db yam o u t hw a s h( a q u ad e s t .1 0m l )f o r
quantitative herpes simplex virus (HSV) DNA testing,
using polymerase chain reaction (PCR) technique. The
dental status, the prevalence of caries (using DMF-T
index) and dental hygiene were assessed by clinical
inspection without staining; dental hygiene was described
semiquantitatively (good—moderate—poor). A previous
academic survey on oral health of a healthy working
population (n=100) served as a control group with respect
to microbiological findings. These (unpublished) data
were intentionally not matched with the study group with
respect to age, health status or socio-economic back-
ground, and were collected by the Institute for Medical
Microbiology, Göttingen in 2006.
The survey was approved by the local ethics authorities.
Statistical methods
The joint occurrence of symptoms and findings was
studied by Fisher's exact test and further described by
odds ratios. The global significance level was set to α=5%
and due to the testing of multiple endpoints corrected
according to the method of Bonferroni. Statistical analyses
were carried out with the free software R (version 2.8,
www.r-project.org).
Results
Patients
Within 8 months, 171 consecutive inpatients were surveyed
and 101 patients were enrolled in this study (patients not
included had refused study participation or were in a
severely compromised general status). Table 1 lists the
demographic characteristics of the study population. The
most prevalent underlying disease entity was cancer of the
gastrointestinal tract (30 patients) and bronchial carcinoma
(22 patients), whilst head and neck tumours, affecting
directly the oral cavity, contributed in only 2 patients. All
patients suffered from cancer; there were no patients with
leading non-cancer disease. Oral care was performed in an
individualized (i.e. non-standardised) manner. Pain syn-
dromes (other than pain of the oral cavity), fatigue and
weakness were the most often self-reported general phys-
ical symptoms in Midos. From these general characteristics,
the surveyed patient group was comparable to other
palliative care patient collectives [2].
Symptoms
Self-reported symptoms (Table 2) comprised dry mouth (83
patients), taste disturbances (68 patients), dysphagia (29
patients), halitosis (26 patients) and pain of the oral cavity
(4 patients). The intensity of these specific symptoms was
described from quite low (NRS 0–1) or moderate (NRS 4–
5) to quite high (NRS 9–10), reflecting the whole spectrum
without main focus (Table 3).
The occurrence of specific symptoms of the oral cavity
in patients taking sedative, anticholinergic or analgesic
medication was found to be very high (e.g. 97% likelihood
for dry mouth in patients receiving morphine, or 81%
likelihood of taste disturbances in patients taking loraze-
pam), but only a minority of patients with dry mouth or
taste disturbances received opioids or lorazepam, owing
tribute to the heterogenous and non-uniform intake of
medications in the study population. A significant correla-
tion between symptoms and drugs could therefore not be
verified.
532 Support Care Cancer (2012) 20:531–537Clinical and microbiological findings
Clinical inspection revealed mainly unremarkable age-
adjusted findings (DMF-T ranging from 7.5 on average in
the age group 30–40 years, and 24.8 in the age group
80 years and older; Table 4).
Plaques not resembling Candida/thrush were the most
prevalent finding on clinical examination (Table 2). An
abnormal bacterial spectrum, defined as quantitative alter-
ations of otherwise physiologically colonizing bacteria of
the oral cavity and/or evidence of non-physiological
bacteria, was found in 34 patients. In 10 patients, two
distinct species were prominent; 1 patient showed a cluster
of three pathogens (Enterobacter cloacae/Pseudomonas
Clinical/microbiological finding Symptom Total
Pain Dry mouth Halitosis Dysphagia Dysgeusia
Thrush (tongue) 2 22 10 7 17 23
Other plaques (tongue) 4 70 21 26 58 81
Thrush (oral mucosa) 2 30 12 9 23 32
Other plaques (oral mucosa) 3 57 17 22 45 63
Erythema (gingiva) 3 54 20 18 44 62
Oedema (gingiva) 0 16 6 8 15 19
Haematoma (gingiva) 0 4 2 1 4 5
Pressure sore 0 14 5 3 10 15
Aphtous ulceration 1 12 8 5 12 14
Gingiva unremarkable 1 27 5 10 22 36
Oral mucosa unremarkable 1 22 4 8 20 32
HSV PCR+ 2 17 8 4 14 19
Yeasts/candidiasis+ 2 63 18 22 53 72
Abnormal bacterial milieu 1 30 13 13 28 34
Multiresistant bacteria 0 4 2 1 4 4
Total 4 83 26 29 68
Table 2 Absolute frequency of
symptoms, according to clinical
and microbiological findings (n=
101)
Table 1 Patient characteristics (total n=101)
Parameter Absolute numbers
Age distribution
>80 years 12
60–80 years 49
40–60 years 35
20–40 years 5
<20 years 0
Gender distribution
Male 41
Female 60
Antineoplastic therapy
Chemotherapy within last 6 weeks 25
Radiation therapy within last 6 weeks 15
None 61
Underlying disease
Gastrointestinal tract cancer 30
Bronchial carcinoma 22
Breast cancer 14
Gynaecological tumours 6
Lymphoma/leukaemia 6
Renal/urinary tract tumours 5
CNS tumours 5
Prostate cancer 4
Skin cancer 4
ENT tumours 2
Cancer of unknown primary 2
Sarcoma 1
Table 3 Intensity of the most often named symptoms
Dry mouth Taste disturbances
NRS 0 15 10
NRS 1 16 11
NRS 2 4 3
NRS 3 2 2
NRS 4 5 4
NRS 5 19 19
NRS 6 0 0
NRS 7 1 1
NRS 8 4 2
NRS 9 4 2
NRS 10 13 14
Total 83 patients 68 patients
Support Care Cancer (2012) 20:531–537 533putida/Klebsiella oxytoca). Four mouth swabs revealed
multiresistant bacteria (×3 methicillin-resistant Staphylo-
coccus aureus, MRSA; ×1 vancomycin-resistant enterococ-
ci, VRE).
Yeasts were found in mouth swabs of 70 patients, as
compared to 37 subjects of the control group (healthy
working population, Table 5). In 10 patients, two different
Candida spp. were isolated (Table 6). HSV DNA was
detected by PCR in 19 patients, with mean low to moderate
titers.
The microbiological finding of Candida spp. was not
always related to the clinical finding of overt thrush (from
72 patients with yeasts, 28 patients also showed thrush on
mucosa), but in 52 of 72 (61.1%) and 21 of 72 (29.1%),
respectively, of patients with yeasts, no thrush or even other
types of plaques could be found. Patients showing plaques
resembling thrush (defined as white, patchy pseudomem-
braneous plaques on erythematous ground) had a microbi-
ological confirmation of Candida spp. in 20 of 23 (86.9%,
tongue) or 28 of 32 (87.5%, mucosa) of cases, respectively.
Plaques that did not show these clinical characteristics were
still associated with yeasts in microbiological culture in
74.1% (60 of 81, tongue) or 80.9% (51 of 63, mucosa) of
cases. Other possible specifications of oral candidiasis like
hyperplastic type, erythematous type or angular cheilitis
were not differentiated further.
Symptoms versus clinical and microbiological findings
The most prevalent symptoms, dry mouth and taste
disturbances, were reported in all clinically or micro-
biologically defined subgroups. The most prevalent clinical
finding, plaques other than thrush, and the leading
microbiological finding (yeasts in 72 of 101 patients.) was
found in all subgroups defined by symptoms. Significant
(or nearly significant) correlations were demonstrated in
only six pairs of symptoms and findings (Table 7).
However, only the correlation between dry mouth and
other plaques (oral mucosa) is significant compared to a
Bonferroni-adjusted significance level.
Discussion
From a clinical perspective, correlating symptoms and
findings appear to be helpful if certain symptoms (e.g. dry
mouth or taste disturbances) are associated with a specif-
ically treatable finding (e.g. thrush/yeasts), or if certain
clinical or microbiological findings (e.g. yeasts or altered
bacterial spectrum, defined as quantitative or qualitative
alterations of the physiological bacterial spectrum of the
oral cavity) are associated with burdensome symptoms and
therefore imply a need to react. Taking this into consider-
ation, there are only few symptoms that positively predict
the occurrence of a specifically treatable cause (Table 8),
Table 5 Microbiological findings in a healthy working population
(historical control group, n=100)
Microbiological findings Frequency (%)
Candida spp. 37
Streptococcus viridans 11
Escherichia coli 5
Klebsiella pneumoniae 5
Enterococcus faecalis 5
Neisseria species 4
Staphylococcus aureus 3
Coagulase-negative staphylococci 6
Pseudomonas aeruginosa 1
Moraxella catarrhalis 4
Streptococcus pneumoniae 3
Serratia marcescens 1
Group A streptococci 3
An abnormal bacterial spectrum was defined as quantitative alterations
of otherwise physiologically colonizing bacteria of the oral cavity and/
or evidence of non-physiological bacteria
Age Prevalence of caries (average DMF-T index) Dental hygiene
“Poor”“ Moderate”“ Good”
<30 years (n=1) 18 1
30–40 years (n=4) 7.5 1 3
41–60 years (n=35) 17.9 11 8 16
61–80 years (n=49) 22.2 11 21 17
>80 years (n=12) 24.8 6 2 4
Table 4 Age-adjusted preva-
lence of caries and dental hy-
giene
Table 6 Presence of two Candida spp. in 10 palliative care patients
Species Absolute numbers
Candida albicans + Candida lambica 1
Candida albicans + Candida krusei 2
Candida albicans + Candida glabrata 5
Candida tropicalis + Candida glabrata 2
534 Support Care Cancer (2012) 20:531–537and only a few clinical or microbiological findings that
positively predict the occurrence of a symptom (Table 9).
For example, 78% of patients with taste disturbances had a
positive culture result of Candida spp. This was 2.58 times
more frequent as compared to patients without taste
disturbances. As one more example, patients with proven
Candida spp. had a dry mouth in 88% of cases, i.e. 3.11
more often than patients without Candida spp.
Dry mouth and taste disturbances were found in the
majority of this representative cohort of palliative care
patients. These symptoms were most prevalent irrespec-
tive of other clinical and microbiological findings, and
were much more prevalent than in previous epidemio-
logic studies, where symptoms had also been rated by
staff. The results from a previous study, where symptoms
have been rated by relatives, almost approach the actual
figures from self assessment [9]. Plaques were the most
prevalent clinical finding, irrespective of other reported
symptoms or microbiological results. In this respect,
clinical findings differed clearly from oncology patients
under chemo/radiation therapy in other studies, where
mucositis is reported to be an obvious finding in up to
40% [10, 11].
The high incidence of Candida spp. as the leading
microbiological finding denotes the most remarkable result
of the study, showing quite different microbiological
characteristics in the given palliative care population,
almost doubling regular prevalence in healthy subjects.
This finding stands out even more, as the bacterial
environment of the oral cavity was found to be not
relevantly altered compared to a healthy working popula-
tion, with the exception of an increased prevalence of
multiresistant bacteria, obviously related to preceding
hospitalisations.
Also, a relatively low number of our patients (19) have
been positively tested for herpes simplex virus by PCR.
Their spectrum of symptoms did not differ from other
patient subgroups; especially, there was no increase in oral
pain, as might have been suggested. Only two of the four
patients addressing pain as a relevant symptom of the oral
cavity had positive HSV PCR results.
A number of factors like thrush, yeasts, herpes simplex
virus, anticholinergic drugs, benzodiazepines and opioids
etc. went along with the perception of dry mouth, less often
with the perception of altered taste. Significant correlations,
though, predominantly involved the criteria of dry mouth,
Symptom Finding Symptom present p
No Yes
Taste disturbances Presence of Candida 0.06
No 14 (48%) 15 (52%)
Yes 19 (26%) 53 (74%)
Dry mouth Presence of Candida 0.04
No 9 (31%) 20 (69%)
Yes 9 (13%) 63 (87%)
Taste disturbances Abnormal bacterial spectrum 0.03
No 27 (40%) 40 (60%)
Yes 6 (18%) 28 (82%)
Dry mouth Thrush (oral mucosa) 0.05
No 16 (23%) 53 (77%)
Yes 2 (6%) 30 (94%)
Dry mouth Other plaques (tongue) <0.05
No 7 (35%) 13 (65%)
Yes 11 (14%) 70 (86%)
Dry mouth Other plaques (oral mucosa) <0.01
No 12 (32%) 26 (68%)
Yes 6 (10%) 57 (90%)
Table 7 Pairs of findings and
symptoms that frequently come
along with each other
Only the correlation between
dry mouth and other plaques
(oral mucosa) is significant
compared to a Bonferroni-
adjusted significance level
Table 8 Treatable findings accompanying specific symptoms
If symptom Then finding In x % of cases Odds ratio, 95% confidence interval
Taste disturbances Presence of Candida 78% 2.58, [0.96, 6.99]
Dry mouth Presence of Candida 76% 3.11, [0.95, 10.25]
The last column gives the odds ratio of patients with the listed symptom having the finding compared to patients without the symptom
Support Care Cancer (2012) 20:531–537 535taste disturbances or yeasts/thrush respectively. As many
conditions lead to a stereotype symptom pattern, clear
causal relations, as attributed for instance to the role of
anticholinergic drugs or opioids, can hardly be extrapolated
in a complex palliative care setting.
This study allows a description of clinical and
pathobiological associations rather than causal relations.
The remarkably high prevalence of Candida spp. in the
oral cavity may well be a causative factor for oral
symptoms like dry mouth or taste disturbances (and
t h e r e f o r eap o s s i b l et a r g e tf o rempirical antifungal treat-
ment). At the other hand, xerostomia and taste disturban-
ces may rather be caused by salivary gland dysfunction
(suggesting the substitution of saliva or therapeutic
interventions to stimulate the salivary glands), that is
followed by Candida infection. Therefore, future research
agenda should involve efforts for a better understanding of
the complex pathophysiological processes within the oral
cavity of palliative care patients, including the potential
role of cancer itself and its metabolic and immunological
impact.
Nevertheless, even the mere description of clinical and
pathobiological associations might be clinically useful: if a
patient complains about dry mouth, the clinical alertness for
associated Candida infection should be high.
This study faces several more interpretative limitations
Besides the above-named microbiological results, oral
health aspects could not be investigated in all details in
this pilot survey on severely ill patients with incurable
advanced cancer. The semiquantitative assessment of dental
hygiene and the assessment of caries by the DMF-T index
suggest a rather unremarkable standard of oral hygiene and
a relatively uncompromised condition of teeth in the
surveyed patient population, but these items do not
encompass all aspects of oral health. Especially, the
gingival condition and a more detailed look on dental
hygiene, as well as their possible correlations to symptoms
and microbiological outcomes should be a focus in further
studies. Also, patients in severely affected general condition
had to be excluded from further evaluation; therefore, the
prevalence of oral complications might have been even
higher.
The pattern of symptom intensity (Table 4) suggests
practical problems in using the numerical rating scales and
a selection bias towards mean and extreme values.
The pilot character of this study in general opposes
multiple testing for significances for statistical reasons. The
significances that have been calculated despite this meth-
odological obstacle have to be rather interpreted as relevant
correlations, and require prospective confirmation.
A number of aspects concerning the clinical relevance
of several microbiological findings remain under further
debate
In four patients, multiresistant bacteria like MRSA or VRE
were diagnosed incidentally. This sheds light on hygiene
standards or isolation policies, not seldomly conflicting
palliative care priorities.
The “clusters of pathogens”, multiple quantitative and
qualitative bacterial alterations found in 11 patients focus
on the aspects of bacterial colonisation versus infection, and
deserve further consideration. The findings on yeasts and
thrush give a first glimpse on the interdependency of
microbiological and clinical findings and subjective rele-
vance. Conclusions concerning changes over time, like the
likelihood for progression from a subclinical, microbiolog-
ically confirmed yeast colonisation to overt thrush, require
further longitudinal study.
Ten patients had two Candida spp., and the relevance of
antifungal (especially azoles) drug resistance may be
highlighted by this finding, even if antifungal resistance
testing was not performed.
The microbiological criteria of an abnormal bacterial
spectrum that was found in 34 patients and showed to be
comparable to control group persons with respect to preva-
lence and leading pathogens need to be discussed. Also,
anaerobic bacteria were not routinely screeneddueto technical
colonisation reasons, and the microbiological findings that
served as control group were not collected for this purpose.
Table 9 Symptoms accompanying specific clinical or microbiological findings
If finding Then symptom In x % of cases Odds ratio, 95% confidence interval
Presence of Candida Dry mouth 88% 3.11, [0.95, 10.25]
Presence of Candida Taste disturbances 74% 2.58, [0.96, 6.99]
Abnormal bacterial spectrum Taste disturbances 82% 3.12, [1.07, 10.47]
Thrush (oral mucosa) Dry mouth 94% 4.47, [0.95, 42.73]
Other plaques tongue Dry mouth 86% 3.37, [0.93, 11.82]
Other plaques mucosa Dry mouth 90% 4.31, [1.33, 15.65]
536 Support Care Cancer (2012) 20:531–537Furthermore, the survey faces limitations with respect to
missing details about grading of symptoms and signs, about
previously taken antibiotics or antimycotics, food intake on
the day of clinical examination and mouth swab/mouth
wash, respectively.
There are only a few preceding investigations on
palliative care patients that also focus on oral symptoms
(e.g. [12]) or the prevalence of oral infections/colonisations
(e.g. [13]). In these studies, the symptom burden has been
found to be up to 77% (dry mouth [14]), and the prevalence
of microbiologically proven candidiasis was found to be
26%. A recent survey from Norway [15] showed symptom
prevalences and clinical findings similar to our patient
cohort, except from the much higher prevalence of oral pain
that might be attributed to anticancer treatment-related
mucositis.
In these studies, it was not intended to detect possible
associations between subjective local symptoms and
clinical or microbiological findings, though. In order to
extend therapeutic options in oral palliative care, the
preceding and present study contribute to a better
understanding of a comprehensive therapeutic approach.
Conclusion
The burden of symptoms of the oral cavity is not
routinely assessed in palliative care and has obviously
been underestimated in previous studies. As many of
the described clinical, pharmacological or microbiolog-
ical conditions are associatedw i t has t e r e o t y p ep a t t e r n
of oral symptoms, a clinical practice of unilateral
allegations (e.g. towards a negative role of opioids)
cannot be justified. Instead, an increased awareness of
oral problems, a symptom-guided assessment and a
therapeutic approach that prioritises the patients' symp-
toms over diagnostic findings in therapeutic decision
making, seems to be more promising from a palliative
care perspective.
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